Nifty
Sensex
:
:
13967.50
47409.93
-271.40 (-1.91%)
-937.66 (-1.94%)

Pharmaceuticals & Drugs - Veterinary

Rating :
71/99

BSE: 512529 | NSE: SEQUENT

211.95
27-Jan-2021
  • Open
  • High
  • Low
  • Previous Close
  •  215.00
  •  215.95
  •  207.15
  •  216.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  621710
  •  1316.91
  •  229.80
  •  51.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,363.57
  • 67.63
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,618.39
  • N/A
  • 7.17

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.86%
  • 9.51%
  • 18.47%
  • FII
  • DII
  • Others
  • 10.2%
  • 4.51%
  • 3.45%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.22
  • 13.54
  • 4.59

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.11
  • 24.60
  • 8.84

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.97
  • 15.48
  • -45.06

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 4.21
  • 30.73

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.40
  • 3.12
  • 2.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 57.44
  • 26.89
  • 15.88

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
346.27
284.22
21.83%
310.26
278.02
11.60%
300.58
281.90
6.63%
316.42
270.53
16.96%
Expenses
289.88
247.06
17.33%
259.25
239.57
8.21%
255.85
242.91
5.33%
266.44
234.84
13.46%
EBITDA
56.39
37.16
51.75%
51.02
38.44
32.73%
44.74
39.00
14.72%
49.98
35.69
40.04%
EBIDTM
16.29%
13.07%
16.44%
13.83%
14.01%
13.83%
15.80%
13.19%
Other Income
2.64
5.97
-55.78%
1.55
1.31
18.32%
1.83
2.43
-24.69%
0.98
1.99
-50.75%
Interest
7.36
7.84
-6.12%
7.65
8.95
-14.53%
9.33
8.90
4.83%
9.60
8.35
14.97%
Depreciation
13.30
12.46
6.74%
13.03
12.01
8.49%
13.09
10.92
19.87%
13.05
11.16
16.94%
PBT
29.32
22.83
28.43%
31.89
18.80
69.63%
24.14
21.60
11.76%
28.31
18.17
55.81%
Tax
7.96
-1.64
-
7.42
3.50
112.00%
5.91
0.28
2,010.71%
4.25
2.60
63.46%
PAT
21.36
24.47
-12.71%
24.47
15.30
59.93%
18.23
21.32
-14.49%
24.06
15.57
54.53%
PATM
6.17%
8.61%
7.89%
5.50%
7.11%
7.56%
7.60%
5.76%
EPS
0.86
0.86
0.00%
0.84
0.46
82.61%
28.29
0.69
4,000.00%
0.82
0.53
54.72%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,273.53
1,179.24
1,039.31
1,030.59
683.57
624.98
465.36
455.46
326.86
345.81
311.89
Net Sales Growth
14.25%
13.46%
0.85%
50.77%
9.37%
34.30%
2.17%
39.34%
-5.48%
10.88%
 
Cost Of Goods Sold
5,145.99
605.05
543.01
554.23
356.70
311.71
240.72
243.65
181.72
192.27
162.01
Gross Profit
-3,872.46
574.19
496.30
476.36
326.87
313.27
224.65
211.81
145.14
153.53
149.87
GP Margin
-304.07%
48.69%
47.75%
46.22%
47.82%
50.12%
48.27%
46.50%
44.40%
44.40%
48.05%
Total Expenditure
1,071.42
1,008.92
914.37
919.10
643.03
568.27
444.87
438.68
342.51
308.74
266.39
Power & Fuel Cost
-
24.73
23.06
14.66
12.77
26.51
23.32
22.06
23.53
20.21
16.75
% Of Sales
-
2.10%
2.22%
1.42%
1.87%
4.24%
5.01%
4.84%
7.20%
5.84%
5.37%
Employee Cost
-
165.06
145.95
132.07
106.22
88.62
62.39
48.12
41.47
29.40
29.82
% Of Sales
-
14.00%
14.04%
12.81%
15.54%
14.18%
13.41%
10.57%
12.69%
8.50%
9.56%
Manufacturing Exp.
-
83.24
77.73
59.07
57.63
72.14
54.31
52.30
41.42
27.88
33.72
% Of Sales
-
7.06%
7.48%
5.73%
8.43%
11.54%
11.67%
11.48%
12.67%
8.06%
10.81%
General & Admin Exp.
-
56.37
58.35
70.92
48.60
36.44
33.79
43.58
23.96
13.69
15.95
% Of Sales
-
4.78%
5.61%
6.88%
7.11%
5.83%
7.26%
9.57%
7.33%
3.96%
5.11%
Selling & Distn. Exp.
-
45.16
36.29
36.87
28.78
17.46
20.27
12.30
10.51
9.23
7.52
% Of Sales
-
3.83%
3.49%
3.58%
4.21%
2.79%
4.36%
2.70%
3.22%
2.67%
2.41%
Miscellaneous Exp.
-
29.32
29.98
51.29
32.34
15.40
10.07
16.66
19.91
16.05
7.52
% Of Sales
-
2.49%
2.88%
4.98%
4.73%
2.46%
2.16%
3.66%
6.09%
4.64%
0.20%
EBITDA
202.13
170.32
124.94
111.49
40.54
56.71
20.49
16.78
-15.65
37.07
45.50
EBITDA Margin
15.87%
14.44%
12.02%
10.82%
5.93%
9.07%
4.40%
3.68%
-4.79%
10.72%
14.59%
Other Income
7.00
10.09
8.67
17.20
11.08
14.30
9.96
3.84
4.96
10.48
6.69
Interest
33.94
35.71
32.80
39.70
28.34
38.56
44.37
39.04
33.45
29.99
23.80
Depreciation
52.47
50.62
41.92
53.30
40.07
46.22
32.94
32.60
28.61
22.98
20.69
PBT
113.66
94.08
58.88
35.70
-16.80
-13.77
-46.85
-51.00
-72.75
-5.41
7.69
Tax
25.54
12.03
2.01
13.46
-0.41
2.62
3.39
0.58
-8.06
-3.95
7.51
Tax Rate
22.47%
12.79%
3.41%
3.03%
2.44%
-19.03%
-40.50%
-0.53%
11.08%
73.01%
215.80%
PAT
88.12
69.91
48.66
421.57
-13.83
-18.47
-10.74
-110.49
-64.69
-1.40
-0.17
PAT before Minority Interest
80.72
82.05
56.88
430.83
-16.39
-16.39
-11.76
-110.49
-64.69
-1.46
-4.02
Minority Interest
-7.40
-12.14
-8.22
-9.26
2.56
-2.08
1.02
0.00
0.00
0.06
3.85
PAT Margin
6.92%
5.93%
4.68%
40.91%
-2.02%
-2.96%
-2.31%
-24.26%
-19.79%
-0.40%
-0.05%
PAT Growth
14.95%
43.67%
-88.46%
-
-
-
-
-
-
-
 
EPS
3.55
2.81
1.96
16.97
-0.56
-0.74
-0.43
-4.45
-2.60
-0.06
-0.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
742.76
706.69
647.58
976.79
945.71
91.27
56.73
95.00
122.53
123.06
Share Capital
49.67
49.37
48.75
48.75
47.65
30.48
26.74
23.44
21.34
21.23
Total Reserves
679.00
638.43
581.25
912.49
874.01
26.85
-0.37
59.68
101.19
101.82
Non-Current Liabilities
241.56
214.75
227.13
246.20
299.72
277.55
159.23
144.35
104.79
123.22
Secured Loans
107.97
126.94
85.14
141.76
197.50
249.97
150.52
137.32
80.19
90.73
Unsecured Loans
42.09
20.90
18.40
23.38
13.82
0.35
0.56
0.72
0.88
8.46
Long Term Provisions
13.16
30.50
28.54
34.76
28.66
25.70
8.03
6.09
15.49
11.74
Current Liabilities
479.57
440.41
430.93
663.55
290.37
406.09
405.28
345.41
329.56
199.21
Trade Payables
220.38
209.35
160.49
203.04
143.94
90.94
114.59
150.91
123.94
82.61
Other Current Liabilities
92.65
87.80
106.52
259.26
83.23
107.43
56.80
35.63
75.38
37.71
Short Term Borrowings
134.36
127.36
152.41
194.70
56.04
204.31
226.60
151.76
123.34
69.09
Short Term Provisions
32.19
15.90
11.51
6.54
7.17
3.42
7.29
7.12
6.89
9.80
Total Liabilities
1,508.63
1,402.10
1,342.62
1,903.76
1,538.02
921.84
625.82
589.34
562.37
446.25
Net Block
632.23
498.14
475.97
684.33
586.48
474.43
237.59
227.26
229.76
210.76
Gross Block
818.12
638.06
581.74
789.60
643.70
596.25
369.07
330.69
305.11
264.26
Accumulated Depreciation
185.89
139.91
105.77
105.27
57.22
121.82
131.48
103.43
75.35
53.50
Non Current Assets
794.52
795.99
804.61
1,176.02
1,047.48
612.00
359.87
358.31
351.94
282.23
Capital Work in Progress
13.42
22.61
18.04
32.55
23.52
39.06
43.04
88.71
64.07
19.53
Non Current Investment
131.29
179.65
221.73
363.97
360.58
58.04
0.04
1.64
0.04
0.05
Long Term Loans & Adv.
14.40
32.27
31.01
37.51
30.35
36.01
76.06
39.28
55.77
50.87
Other Non Current Assets
3.18
63.31
57.86
57.66
46.54
4.47
3.15
1.42
2.30
1.02
Current Assets
714.11
606.12
538.01
727.74
490.54
309.84
265.94
231.04
210.42
164.02
Current Investments
40.18
0.47
17.34
64.12
66.98
0.58
0.08
0.18
0.28
0.33
Inventories
219.42
200.10
158.57
160.81
135.08
94.36
101.40
85.62
68.24
65.55
Sundry Debtors
318.76
278.25
258.35
254.62
192.39
115.44
83.54
65.81
70.41
55.45
Cash & Bank
75.83
72.04
42.45
47.40
25.30
38.46
36.21
33.00
35.88
9.17
Other Current Assets
59.92
8.51
5.25
146.31
70.80
61.01
44.71
46.44
35.62
33.52
Short Term Loans & Adv.
44.41
46.75
56.05
54.48
46.69
41.86
37.47
36.48
28.84
31.25
Net Current Assets
234.54
165.71
107.08
64.19
200.17
-96.25
-139.34
-114.37
-119.13
-35.19
Total Assets
1,508.63
1,402.11
1,342.62
1,903.76
1,538.02
921.84
625.81
589.35
562.36
446.25

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
115.33
116.02
45.24
-7.19
-0.05
-23.55
-44.78
-3.82
21.48
49.63
PBT
94.08
58.88
445.79
-16.80
-13.77
-8.37
-109.91
-72.75
-5.41
3.49
Adjustment
91.41
84.47
-313.85
123.31
83.81
35.92
133.52
65.98
46.98
36.77
Changes in Working Capital
-58.30
-27.95
-77.87
-104.37
-71.46
-53.98
-67.45
2.48
-17.29
15.96
Cash after chg. in Working capital
127.18
115.40
54.06
2.14
-1.42
-26.44
-43.84
-4.28
24.27
56.22
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-11.85
0.62
-8.83
-9.33
1.37
2.89
-0.95
0.46
-2.79
-6.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-72.27
-67.69
7.17
-116.18
-315.83
-154.69
-79.95
-54.89
-66.78
-71.77
Net Fixed Assets
-29.66
-32.63
221.87
-49.63
97.97
38.51
-26.62
-28.82
-41.67
-80.90
Net Investments
30.56
-101.61
210.25
0.26
-713.97
-118.07
-10.37
-15.66
-25.20
31.50
Others
-73.17
66.55
-424.95
-66.81
300.17
-75.13
-42.96
-10.41
0.09
-22.37
Cash from Financing Activity
-42.75
-20.08
-56.96
147.44
308.69
179.41
145.54
34.70
61.94
16.51
Net Cash Inflow / Outflow
0.31
28.25
-4.55
24.07
-7.19
1.17
20.80
-24.02
16.63
-5.62
Opening Cash & Equivalents
67.79
39.54
44.10
20.03
21.85
22.96
3.45
27.37
9.17
14.07
Closing Cash & Equivalent
68.10
67.79
39.54
44.10
20.03
21.83
22.96
3.45
27.37
9.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
29.34
27.86
25.85
39.44
38.69
3.76
1.97
7.09
11.48
11.59
ROA
5.64%
4.14%
26.54%
-0.95%
-1.33%
-1.52%
-18.19%
-11.23%
-0.29%
-0.97%
ROE
11.58%
8.63%
54.15%
-1.74%
-3.35%
-28.10%
-201.83%
-62.91%
-1.19%
-3.42%
ROCE
12.33%
9.24%
41.28%
0.87%
2.72%
6.93%
-16.09%
-9.86%
6.98%
9.11%
Fixed Asset Turnover
1.65
1.74
1.51
0.96
1.03
1.01
1.36
1.08
1.26
1.31
Receivable days
90.45
92.53
90.49
118.40
87.75
74.80
57.30
72.70
64.08
63.08
Inventory Days
63.56
61.85
56.34
78.37
65.41
73.58
71.75
82.12
68.11
69.36
Payable days
80.87
75.36
77.04
104.11
77.28
87.31
115.68
149.32
123.09
94.20
Cash Conversion Cycle
73.14
79.02
69.78
92.66
75.87
61.07
13.36
5.51
9.10
38.25
Total Debt/Equity
0.45
0.47
0.48
0.43
0.34
8.26
15.86
3.74
2.19
1.54
Interest Cover
3.63
2.80
12.19
0.41
0.64
0.81
-1.82
-1.18
0.82
1.15

News Update:


  • SeQuent Scientific launches Citramox LA in EU
    10th Dec 2020, 14:48 PM

    This new approval for SeQuent builds on the recent approvals of Tulazzin (Tulathromycin) and Halofusol (Halofuginone) in Europe

    Read More
  • Sequent Scientific launches Halofusol Oral Solution in European countries
    1st Dec 2020, 11:38 AM

    The company is also planning to extend the launch to other geographies

    Read More
  • Sequent Scientific - Quarterly Results
    6th Nov 2020, 14:41 PM

    Read More
  • Sequent Scientific completes acquisition of 40% stake in Provet
    3rd Nov 2020, 10:45 AM

    On completion of the said transaction, Provet has become a Wholly Owned Subsidiary of the Company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.